American corporation's patenting of breast cancer gene overturned
8 Oct 2007
A controversial patent, granted to Myriad Genetics in 2001, which laid claim to a gene indicative of predisposition to breast cancer, has been scrapped for good, it was reported in the Telegraph today.
EP699754 ensured a monopoly on testing for BRCA1 and meant that Myriad could charge up to $3000 for testing. After six years of opposition from scientists and patients alike, the European Patent Office (EPO) ruled that the corporation did not have a justified claim of ownership and that the patent would hinder further research.
Tests for BRCA1 are now expected to decrease to less than $1000 (around £500).
EPO’s decision has been welcomed by both scientists and patients; being seen as a landmark for the greater good over financial gain.
Help every cancer patient get the care they deserve
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.